PHIOPhio Pharmaceuticals Corp.
The Read
1% when mid-2026 oncology updates failed to deliver new data or partnerships.
The schedule
- Thu15Oct
Expected IND/CTA filing or clearance for PHIO’s lead RNAi immuno-oncology program. A timely regulatory submission or acceptance with a clear Phase 1 plan could re-rate the stock toward $1.25, while delay, additional information requests, or failure to file could undermine confidence in the platform and pressure the stock toward $1.25 by the outcome date.
- Tue15Dec
Window for potential strategic partnership announcements or inbound M&A interest around PHIO’s RNAi immuno-oncology platform. A credible collaboration with a larger oncology player or a formal strategic review could lift the stock toward $1.60, while the absence of deals, combined with financing needs, could unwind speculative premium and push shares toward $1.60 by the outcome date.
- Mon15Feb
Q3 2026 earnings release focused on updated cash balance and spending levels after regulatory progress on the lead RNAi program. Confirmation that cash burn is in line with expectations and that runway extends into late 2027 without urgent dilution risk could support a drift higher toward $1.32, while a larger-than-expected burn or signals of near-term equity financing could pull the stock back toward $1.32 by the outcome date.
- Thu6May
- Mon24May
Q4 2026 earnings release with detailed 2027 cash runway guidance and any updates on financing, partnerships, or trial pacing. Confirmation that PHIO can fund key clinical milestones through at least late 2027, potentially via non-dilutive capital or disciplined spending, could support a recovery toward $0.70, whereas signs of a short runway or dilutive equity financing could drag the stock toward $0.70 by the outcome date.
Past
- Thu13Aug
Actual outcome: Mixed
Phio Pharmaceuticals reported Q2 2026 earnings that exactly met expectations with an EPS of -$0.34, alongside strategic milestone advancements for its lead clinical candidate PH-762 and a new U.S. Notice of Allowance for its INTASYL composition. Despite these positive pipeline updates, the lack of significant upside surprises or clear catalysts regarding cash runway left investors neutral, resulting in flat price action over the period.
Q2 2026 earnings and pipeline update, with focus on cash burn, runway into 2027, and prioritization of PH-762 and other RNAi oncology programs. A constructive update on trial timelines and partnering could lift the stock toward $1.12, while continued cash burn without clear catalysts or financing visibility could push it down toward $1.12 by the outcome date.
- Fri31Jul
Actual outcome: Mixed · $1.09 at outcome
During the period, Phio Pharmaceuticals did not announce the anticipated equity financing or ATM usage to extend its cash runway. The only notable developments were the appointment of a new board member and participation in a non-deal roadshow, leading to a muted 1.0% price movement as the market awaited clearer funding updates.
With no revenue and ongoing quarterly losses, PHIO is likely to consider an equity raise or ATM usage around mid-2026 to lengthen its RNAi oncology development runway, which can either be viewed as strategic de-risking or as dilutive pressure from the $1.10 level.
- Wed3Jun
Actual outcome: Bear · $1.01 at outcome
Phio Pharmaceuticals did not release any significant clinical data or platform updates around the anticipated mid-2026 timeframe, only announcing participation in a non-deal roadshow. The absence of meaningful pipeline progress or partnership developments disappointed investors, causing the stock to decline 8.1% and fall below the bear floor.
Around mid-2026, PHIO is likely to highlight preclinical or early translational data for its RNAi-based immuno-oncology platform at major cancer meetings, which can reframe perceptions of the pipeline’s differentiation and partnership potential from the $1.00 base.
- Thu7May
Actual outcome: Bear · $1.08 at outcome
Phio reported in-line Q1 2026 earnings with an EPS of -$0.20 and announced the completion of its PH-762 dose escalation trial for skin cancer, highlighting favorable safety and pathology data. Despite these clinical milestones and securing key manufacturing agreements, the stock drifted 5.3% lower toward the bear floor. The lack of definitive updates on extending the cash runway or broader pipeline monetization likely left investors cautious, prompting a gradual decline in the share price.
Q1 2026 results should focus on operating burn, cash runway beyond 2027, and any clarity on prioritizing Phio’s lead RNAi immuno-oncology programs. With no revenue and a negative enterprise value, incremental detail on cost discipline and trial sequencing can move the stock away from the current $1.25 range.
